Patient Experience With The Single-Use Pen For Injection of Once Weekly Dulaglutide in Injection-Naive Patients With Type 2 Diabetes
نویسندگان
چکیده
منابع مشابه
Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
Glucagon-like peptide-1 (GLP-1) analogs, such as exenatide, have played an important role as antidiabetic medications in the treatment of type 2 diabetes (T2DM). Like most other hypoglycemic agents, exenatide has a number of actions, including lowering blood glucose, promoting weight loss, improving insulin resistance, and protecting islet β-cells. Although GLP-1 analogs, combined with other an...
متن کاملSimilar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years
AIMS To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in elderly patients (aged ≥65 years) with type 2 diabetes (T2D) in six phase III clinical trials. METHODS Patients were grouped into two age groups: ≥65 and <65 years. Pooled analysis for glycated haemoglobin (HbA1c) change from baseline, percentage of patients achieving HbA1c targets, and gastrointestinal tolerability we...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once‐weekly dulaglutide treatment
AIM To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials. METHODS At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy. The effect of baseline...
متن کاملExenatide once weekly in type 2 diabetes.
The difficulties of maintaining long-term glycaemic control with available antidiabetic treatments in patients with type 2 diabetes have led to the need for additional treatments that can replace or be safely combined with existing agents. Patients with type 2 diabetes who have not achieved adequate glucose control at the maximum tolerated doses of their oral therapies have had no alternative o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2014
ISSN: 1098-3015
DOI: 10.1016/j.jval.2014.08.747